Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CATX NASDAQ:DRTS NASDAQ:NTRB NASDAQ:SKIN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCATXPerspective Therapeutics$3.38-6.4%$3.79$1.60▼$16.31$251.01M1.17930,663 shs490,718 shsDRTSAlpha Tau Medical$3.36-0.3%$3.13$2.11▼$4.39$285.84M0.9964,073 shs31,012 shsNTRBNutriband$6.53+1.9%$7.60$3.72▼$11.78$71.50M1.13189,489 shs13,988 shsSKINBeauty Health$2.04-0.5%$1.94$0.78▼$2.56$259.99M1.21.44 million shs518,233 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCATXPerspective Therapeutics-6.37%-5.06%-13.78%+31.52%-77.87%DRTSAlpha Tau Medical-0.30%+7.01%+15.86%+13.51%+48.02%NTRBNutriband+1.87%+3.49%-13.40%+4.98%+45.76%SKINBeauty Health-0.49%-1.45%+20.71%+24.01%+15.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCATXPerspective Therapeutics1.3837 of 5 stars3.61.00.00.01.60.80.0DRTSAlpha Tau Medical3.0451 of 5 stars3.55.00.00.02.81.70.0NTRBNutriband3.3501 of 5 stars3.55.00.00.02.81.70.6SKINBeauty Health1.6061 of 5 stars3.00.00.00.02.73.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCATXPerspective Therapeutics 3.18Buy$12.56271.47% UpsideDRTSAlpha Tau Medical 3.00Buy$9.00167.86% UpsideNTRBNutriband 3.00Buy$13.0099.08% UpsideSKINBeauty Health 2.00Hold$2.6328.68% UpsideCurrent Analyst Ratings BreakdownLatest NTRB, SKIN, DRTS, and CATX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/1/2025SKINBeauty HealthStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$3.00 ➝ $4.007/12/2025CATXPerspective TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/23/2025CATXPerspective TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $12.006/23/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.006/3/2025CATXPerspective TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$15.00 ➝ $16.00(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCATXPerspective TherapeuticsN/AN/AN/AN/A$2.67 per shareN/ADRTSAlpha Tau MedicalN/AN/AN/AN/A$1.02 per shareN/ANTRBNutriband$2.14M34.02N/AN/A$0.58 per share11.26SKINBeauty Health$334.30M0.77$0.06 per share32.42$0.58 per share3.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCATXPerspective Therapeutics-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%11/11/2025 (Estimated)DRTSAlpha Tau Medical-$31.75M-$0.48N/AN/AN/AN/A-51.21%-38.18%N/ANTRBNutriband-$10.48M-$0.90N/AN/AN/A-415.93%-68.25%-60.40%9/2/2025 (Estimated)SKINBeauty Health-$29.10M-$0.28N/AN/AN/A-6.13%-32.82%-2.96%11/11/2025 (Estimated)Latest NTRB, SKIN, DRTS, and CATX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/2/2025N/ANTRBNutriband-$0.17N/AN/AN/A$0.71 millionN/A8/11/2025Q2 2025DRTSAlpha Tau Medical-$0.12-$0.13-$0.01-$0.13N/AN/A8/7/2025Q2 2025SKINBeauty Health-$0.06$0.03+$0.09$0.03$74.67 million$78.20 million5/30/2025Q1 2026NTRBNutriband-$0.13-$0.12+$0.01-$0.12$0.71 million$0.67 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCATXPerspective TherapeuticsN/AN/AN/AN/AN/ADRTSAlpha Tau MedicalN/AN/AN/AN/AN/ANTRBNutribandN/AN/AN/AN/AN/ASKINBeauty HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCATXPerspective TherapeuticsN/A9.609.60DRTSAlpha Tau Medical0.0710.525.81NTRBNutriband0.013.713.48SKINBeauty Health4.915.154.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCATXPerspective Therapeutics54.66%DRTSAlpha Tau Medical2.65%NTRBNutriband19.70%SKINBeauty Health93.26%Insider OwnershipCompanyInsider OwnershipCATXPerspective Therapeutics3.72%DRTSAlpha Tau Medical39.50%NTRBNutriband54.09%SKINBeauty Health41.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCATXPerspective Therapeutics7074.26 million65.21 millionOptionableDRTSAlpha Tau Medical8084.82 million51.32 millionNo DataNTRBNutriband1011.15 million5.12 millionNot OptionableSKINBeauty Health1,030126.82 million74.83 millionOptionableNTRB, SKIN, DRTS, and CATX HeadlinesRecent News About These CompaniesHow Lindsay Lohan restored the beauty and youth of her face: secrets revealedAugust 28 at 4:50 PM | msn.comElsa Pataky reveals the beauty secret she learned from her mother: 'I love that it's stuck with me'August 28 at 4:50 PM | hola.comHYou've Definitely Seen Hypochlorous Acid Spray All Over Social Media. Here's What It Does For Skin.August 28 at 4:50 PM | msn.comDebut secures $20 million to enhance skin longevity ingredient researchAugust 27 at 10:15 AM | cosmeticsbusiness.comCBoost Collagen Naturally With These Skin Care TipsAugust 27 at 10:15 AM | msn.comHair loss sufferers 'couldn't believe' growth of hair boosted by beauty bundleAugust 27 at 10:15 AM | express.co.ukI Tried This Beauty Device That Promises to Transform Aging Skin in Just 3 Minutes—and the Results Are SurprisingAugust 27 at 10:15 AM | msn.com6 Ways Bella Hadid Redefined Natural and Sophisticated BeautyAugust 26 at 12:13 AM | msn.comSharon Chuter, who revolutionised beauty and called out industry hypocrisy, dies at 38August 26 at 7:12 PM | msn.comDebut Raises $20M to Fast-track AI Ingredient Discovery in Skin Longevity and Grow its Formulation Business in the US and AsiaAugust 26 at 7:12 PM | finance.yahoo.comHow Jennifer Lopez keeps her skin radiant over 50: 15 tried-and-true trickAugust 26 at 7:12 PM | msn.comWho Cares if You’re Healthy So Long as You Look Good?August 26 at 7:12 PM | nytimes.comFirm taps AI decoder to promote skin health, recommend solutionsAugust 26 at 7:12 PM | businessday.ngBExactly How To Exfoliate Your Face—Without Ruining Your SkinAugust 26 at 7:12 PM | msn.comBeauty benefits of green tea: radiant skin and healthy hairAugust 26 at 7:12 PM | msn.comGut Ready With Me: Turning Gut Health Into the Ultimate Beauty RoutineAugust 26 at 7:12 PM | latimes.comEver heard of a skincare sommelier? Here’s how your skin routine could benefit from seeing oneAugust 25, 2025 | bodyandsoul.com.auBThe Dark Side of Skincare: Is "Cosmeticorexia" Ruining Your Skin and Your Wallet?August 25, 2025 | msn.comThe ‘ABCDEs’ of skin cancer — and 9 clues you shouldn’t ignoreAugust 25, 2025 | nypost.comNFrom Multi-Stacking To PDRN, These Are The Korean Tweakment Secrets Behind Glass SkinAugust 25, 2025 | msn.comBeauty Health (NASDAQ:SKIN) Upgraded by Wall Street Zen to Buy RatingAugust 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNTRB, SKIN, DRTS, and CATX Company DescriptionsPerspective Therapeutics NYSE:CATX$3.38 -0.23 (-6.37%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$3.40 +0.02 (+0.59%) As of 04:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.Alpha Tau Medical NASDAQ:DRTS$3.36 -0.01 (-0.30%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$3.26 -0.10 (-2.95%) As of 08/28/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.Nutriband NASDAQ:NTRB$6.53 +0.12 (+1.87%) Closing price 08/28/2025 03:59 PM EasternExtended Trading$6.55 +0.02 (+0.32%) As of 08/28/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.Beauty Health NASDAQ:SKIN$2.04 -0.01 (-0.49%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$2.08 +0.04 (+2.21%) As of 04:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It NIO Just Got Its Second Upgrade of the Month, and It’s Big Chevron Stock Outlook: Dividend Growth Meets Inflation As Bitcoin Falls and Ethereum Rallies, Coinbase Stock Comes Back Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access